Frazier Reduces Holdings in Soleno

Summary

Frazier Life Sciences Management L.P. decreased its holding in Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 20.2% during the fourth quarter, currently holding 699,159 shares. Other hedge funds also adjusted their positions. Insiders have recently sold 942,672 shares. SLNO stock opened at $75.05 with a market cap of $3.78 billion. Analysts have raised the target price, with Robert W. Baird setting it at $105.00 and Guggenheim at $97.00, both rating the stock as ‘buy’ or ‘outperform’.Market Beat

Impact Analysis

This event is at the company level, focusing on Soleno Therapeutics. The reduction in holdings by Frazier Life Sciences may signal a reevaluation of Soleno’s prospects or a shift in investment strategy. However, the positive analyst ratings and increased target prices from Robert W. Baird and Guggenheim suggest strong market confidence and potential upside. First-order effects include potential volatility due to insider sales and hedge fund adjustments, while second-order effects might include increased attention on Soleno from other investors or firms seeking opportunities based on analyst optimism. Investment opportunities could involve buying SLNO stock based on analyst recommendations, although risks could include potential market overreaction to insider selling.Market Beat